Genmab A/S (NASDAQ:GMAB) is a global biotechnology company focused on the creation and development of innovative antibody therapeutics for the treatment of cancer and other serious diseases. Headquartered in Copenhagen, Denmark, the firm leverages proprietary antibody technologies to generate novel drug candidates and advance them through clinical development. Since its inception in 1999, Genmab has established a strong reputation for pioneering bispecific and antibody-drug conjugate platforms that aim to improve patient outcomes by targeting disease pathways with high precision.
The company’s research and development efforts are concentrated on immuno-oncology, using its DUOBODY® bispecific antibody platform to engage two targets simultaneously and enhance immune response against tumor cells. Genmab also applies its GENmab’s HexaBody® and DuoHexaBody® technologies to amplify the immune system’s ability to destroy cancer cells, as well as its ADCC-Enhancer™ technology to increase the potency of monoclonal antibodies. These platforms support a diverse pipeline of clinical-stage candidates in various hematologic and solid tumor indications, often in collaboration with strategic partners.
Genmab has achieved commercial success through collaborations that bring its antibody innovations to market. The company co-developed and licenses several landmark therapies, including the anti-CD38 antibody daratumumab (marketed as DARZALEX®) for multiple myeloma, and the anti-PD-1 antibody combination epcoritamab (developed with AbbVie) for B-cell malignancies. In addition to oncology, Genmab is exploring opportunities in rare and autoimmune diseases, leveraging its expertise in antibody engineering to expand into new therapeutic areas.
Operating globally, Genmab maintains research and development facilities in Denmark and the United States, with commercial and clinical capabilities supported by partnerships in Europe, North America, and Asia. The company’s leadership team is led by CEO Jan van de Winkel, Ph.D., who has guided Genmab through a period of rapid growth and innovation. Under his direction, the board and executive management continue to prioritize cutting-edge science, regulatory excellence, and strategic collaborations to drive long-term value and deliver transformative medicines to patients worldwide.
